24804-1

Delete

ISU to begin canine anticancer immunotherapeutic agent clinical trials

The school is teaming up with Canadian company NovaVive to conduct a clinical study

Suggested Veterinary Products

Iowa State University (ISU) College of Veterinary Medicine is starting a clinical study for a new canine anticancer immunotherapeutic.

Produced by NovaVive, the anticancer treatment, Immunocidin, has received regulatory approval in the U.S. and Canada to treat mammary tumors. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored.

“Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades,” said Chad Johannes, DVM, DACVIM (SAIM, oncology). “Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs.”

Ten oncology clinics will participate in the trial. To find one, visit bit.ly/2D56wBv and enter AAHSD004874 in the keyword search.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.